Core2Edge: A Security & Compliance Approach to Mapping Glioblastoma Invasion
Glioblastoma doesn't just grow. It spreads. It slips past surgical margins, buries itself in healthy brain tissue, and waits. We've known this for years. What we haven't had is a reliable way to watch it happen in real-time, in human tissue, without relying on animal models that simply don't behave like humans.
Enter Core2Edge.
Developed by a research team at the University of Bonn and published in Nature Protocols in 2026, Core2Edge is an ex vivo model that combines patient-derived glioblastoma organoids (GBOs) with organotypic human brain-slice cultures. It maps single-cell tumor invasion in three dimensions, capturing both the spread of infiltrating cells and the genetic diversity that makes these tumors so damn difficult to treat.
From a security & compliance analyst's perspective, you look at a system, find the vulnerabilities, and document exactly how they're exploited. Core2Edge does exactly that for glioblastoma. It doesn't gloss over the messy, invasive reality of the disease. It maps it. Cell by cell.
The Security & Compliance of a Human-Centric Model
The model starts with patient material. Glioblastoma organoids are grown from freshly resected tumor tissue—essentially miniature tumors cultivated in a lab dish. Meanwhile, brain slices are prepared from tissue routinely removed during neurosurgical procedures to access deeper target regions. This tissue would normally be discarded. Core2Edge gives it a second life, and more importantly, it gives researchers a compliant, human-centric framework for studying tumor behavior.
The organoids get implanted into the brain slices and co-cultured. From there, researchers can track tumor spread from the core of the tumor all the way out to individual infiltrating cells, exactly as they'd appear in a patient's brain.
Visualization happens through high-resolution light-sheet fluorescence microscopy. After fixation, the tissue is physically expanded to improve light penetration and clarify fine structures. Then the sample gets scanned layer by layer, creating three-dimensional images of the entire tumor-infiltrated brain volume—at single-cell resolution.
"This allows us not only to quantify tumor cell spread in three dimensions, but also trace morphology down to individual infiltrating cells," said first author Ahmad Melhem, who developed Core2Edge as part of his doctoral research.
Mapping the 365-Day Recurrence Window
Glioblastoma cells vary wildly in their genetic activity, even within a single tumor. This intratumoral heterogeneity is a key driver of therapy resistance. Some cell populations survive radiation. Others resist chemotherapy. Together, they rebuild the tumor.
Core2Edge captures this diversity. Spatial transcriptomics—the technology that maps which genes are active in individual cells while preserving their exact physical coordinates—confirmed that the model preserves the complex genetic heterogeneity seen across different zones of the original tumor.
In clinical practice, recurrence often happens within a 365-day window post-surgery. Core2Edge allows researchers to simulate and study these rapid recurrence dynamics in a controlled environment, identifying exactly which cellular programs are active in the infiltration zones. "We were able to show that Core2Edge recapitulates intratumoral heterogeneity. This provides further evidence that the model closely reflects the situation in patients," noted Dr. Anna-Laura Potthoff, a neurosurgeon and clinician scientist with the Bonn research group.
The Protocol in Practice
Once glioblastoma organoids are prepared, the Core2Edge protocol takes roughly 7 to 12 days to complete. Brain slice preparation alone runs 4 to 6 hours, depending on quantity. There's a day for initial culture before organoid staining and transplantation, followed by a variable culture period of up to 10 days, and about 8 hours for fixation. The whole process demands experience with both human brain slice culture and organoid techniques.
But the payoff is significant. Researchers can study initial infiltration steps, analyze the invasive front in depth, and explore cell-to-cell interactions between tumor cells and their microenvironment. It's also a platform for drug screening and testing.
A Human-Centric Alternative to Animal Models
One of Core2Edge's quieter advantages is ethical. By modeling glioblastoma invasion directly in human neural architecture, the platform reduces reliance on animal experiments. Key aspects of glioblastoma biology—particularly infiltration and intratumoral heterogeneity—can be studied directly in human tissue.
"Core2Edge offers a scientifically and ethically compelling alternative to animal models," said Dr. Matthias Schneider, Deputy Director of the Department of Neurosurgery at the University Hospital Bonn (UKB) and head of the Brain Tumor Translational Research Group at both UKB and the University of Bonn.
Related Research
For more on glioblastoma biology and treatment approaches, see:
- Unlocking Sex-Specific Vulnerabilities: GABA Pathway Fuels Glioblastoma in Females
- A Dual-Pronged Approach to Attacking Glioblastoma's Immune Shield
- Hetairos AI: 12-Minute Brain Tumor Molecular Classification from Histology Slides
Research Context
The study involved researchers from multiple Bonn institutions: the Department of Neurosurgery (led by Prof. Dr. Hartmut Vatter), the Department of Neuro-Oncology (Prof. Dr. Ulrich Herrlinger), and the Department of Neuropathology (Prof. Dr. Torsten Pietsch). Collaborators included scientists from the Clausius Institute for Physical and Theoretical Chemistry, the Life & Medical Sciences Institute (LIMES), the Institute for Experimental Epileptology and Cognitive Research, and the Institute for Experimental Oncology.
Funding came from the Mildred Scheel School of Oncology (MSSO) Cologne-Bonn of German Cancer Aid, the Ministry of Culture and Science of North Rhine-Westphalia through the CANTAR (CANcer TARgeting) research network, and the German Research Foundation.
The full research paper—"Core2Edge: A human glioblastoma organoid-brain slice model capturing infiltration and transcriptional heterogeneity from core to single-cell dispersion"—is available open access in Nature Protocols (DOI: 10.1038/s41596-026-01412-3).
Evidence Ledger
All claims in this article are sourced from the Neuroscience News coverage of University of Bonn research published in Nature Protocols.
Source: https://neurosciencenews.com/core2edge-glioblastoma-brain-cancer-31144/
- Core2Edge is an advanced ex vivo human tissue model that replicates the invasive spread and molecular diversity of glioblastoma
- The model combines patient-derived glioblastoma organoids with organotypic human brain-slice cultures
- It enables high-resolution spatial tracking of infiltrating tumor cells into healthy brain tissue
- The platform integrates light-sheet fluorescence microscopy with spatial transcriptomics to map cell migration and gene expression at single-cell resolution
- Core2Edge was developed by Ahmad Melhem, Matthias Schneider, Anna-Laura Potthoff, and colleagues at the University of Bonn/UKB
- The research was published in Nature Protocols (DOI:10.1038/s41596-026-01412-3)
- Glioblastoma cells migrate deep into healthy brain parenchyma beyond surgical margins, serving as the primary source for rapid tumor recurrence post-treatment
- The model uses human brain slices derived from routinely discarded neurosurgical tissue
- Physical tissue expansion is combined with light-sheet fluorescence microscopy to generate whole-volume 3D reconstructions at single-cell resolution
- Spatial transcriptomics confirms that Core2Edge preserves complex intratumoral genetic heterogeneity across different tissue zones
- Core2Edge minimizes dependency on animal models while improving translational accuracy
- The protocol takes approximately 7-12 days once GBOs are prepared
- The model allows study of initial infiltration steps, analysis of the invasive front, and exploration of cell-cell interactions between tumor cells and the tumor microenvironment